Innovative Antifungal Drugs Saving Lives Worldwide
Biosergen is a biotech company dedicated to developing groundbreaking antifungal drugs. Our lead product, BSG005, offers superior safety and potency compared to existing treatments. We aim to provide hope and healing to immunocompromised patients, including those with AIDS, cancer, and transplant recipients.
2.5 Milion Dies from Fungal Disease Each Year
Globally,it is estimated that over 6.55 million people are affected by an immediately life-threatening fungal disease each year, resulting in over 3.75 million deaths, of which about 2.55 million are directly attributable to fungal diseases. WHO recognize this as a global health threat.
Providing Effective Antifungal Solutions
Biosergen’s mission is to develop drug candidates into a novel first line treatment choice for life-threatening fungal diseases, to save the lives of immuno-compromised patients including patients with AIDS, cancer and transplant recipients.
Share & Investor Information
Biosergen’s shares are listed on the Nasdaq First North Growth Market, Stockholm (OMX: BIOSGN).
Advancing Antifungal Innovation
Discover how Biosergen is revolutionizing antifungal treatment with BSG005, a ground breaking drug invented at Norwegian University of Science and Technology in collaboration with SINTEF, Norway
Superior Safety
BSG005 is designed to be safe, Phase 1 study in 38 healthy individuals showed no significant side effects. Offering hope to immunocompromised patients worldwide.
Cutting-Edge Solution
BSG005 is a genetically improved polyene macrolide that targets a wide spectrum of fungus genus and is fungicidal, thus kills the fungus and not only inhibits growth.
Superior Antifungal Treatment for Immunocompromised Patients
BSG005 was invented at Norwegian University of Science and Technology in collaboration with SINTEF, Norway and further developed globally. BSG005 is a ground breaking antifungal drug that aims to treat invasive fungal infections in immunocompromised patients. With superior safety and potency compared to current treatments, BSG005 offers hope to individuals with AIDS, cancer, and transplant recipients.
Comprehensive Treatment for Invasive Fungal Infections
BSG005 targets a wide range of invasive fungal infections, providing effective solutions for immunocompromised patients.
Improved Quality of Life for Patients
By treating invasive fungal infections, BSG005 helps immunocompromised patients regain their health and improve their overall well-being.
Cutting-Edge Research and Development
Our team of experts is dedicated to advancing antifungal drug development through innovative research and development processes.
Pioneering Treatment for Life-Threatening Fungal Infections
In collaboration with Alkem Laboratories Limited, one of India's top pharmaceutical leaders, Biosergen is advancing groundbreaking research to combat severe fungal infections. The ongoing Phase 1B trial, fully funded by Alkem, is showing promise, with the first patient treated with BSG005 surviving as rescue therapy. With commercial rights secured in India by Alkem and globally by Biosergen, this treatment is poised to revolutionize care for patients with resistant fungal strains. Patents ensure protection until 2043, and the FDA’s orphan drug status guarantees market exclusivity in the U.S. for 5 years post-approval.
Latest Press Releases
Discover the Power of BSG005
Learn more about our innovative antifungal drug, BSG005. Contact Biosergen for further information.